Neurocrine Biosciences NBIX Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's business segments — total revenues?
- Neurocrine Biosciences (NBIX) reported business segments — total revenues of $814.5M in Q1 2026.
- How has Neurocrine Biosciences's business segments — total revenues changed year-over-year?
- Neurocrine Biosciences's business segments — total revenues increased by 42.2% year-over-year, from $572.6M to $814.5M.
- What is the long-term trend for Neurocrine Biosciences's business segments — total revenues?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — total revenues has grown at a 24.3% compound annual growth rate (CAGR), from $1.49B to $2.86B.
- What does business segments — total revenues mean?
- Represents the total gross income generated by the company's primary business operations, including product sales and collaboration revenues. This metric reflects the market demand for the company's pharmaceutical portfolio and its ability to monetize clinical assets.